Are you attending LTEN June 13- June 15 in San Antonio, Texas? Don't miss our workshop “Biosimilars: Shifting Access Strategies in the Payer and Health Systems Market” on June 15 at at 2:00 pm featuring Precision's Ryan Cox, Erica Gaeta, and Dan Vanderpoel.
A rule slated to take effect January 1, 2023 would reverse CMS' long held position that manufacturer-provided assistance given to patients is excluded from best price and average manufacturer price calculation for prescription drugs. The rule change could potentially result in increased patient out-of-pocket costs for drugs and pharma companies being on the hook for ensuring they know exactly where their assistance is going.
Modern technology allows for the mass collection of digital health data. Artificial intelligence has become a vital tool for making sense of the huge volume of health data being collected daily through the use of big data analytics (BDA).
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
